Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling

European Journal of Medicinal Chemistry

Volumn 46, Issue 6, 2011, Pages 2513-2529

  Al Najjar, Belal O ^a   Wahab, Habibah A ^a,b   Tengku Muhammad, Tengku Sifzizul ^b,c   Shu Chien, Alexander Chong ^b   Ahmad Noruddin, Nur Adelina ^b   Taha, Mutasem O ^d  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b SCHOOL OF PHYSICS   (Malaysia)

^c UNIVERSITI MALAYSIA TERENGGANU   (Malaysia)

^d UNIVERSITY OF JORDAN   (Jordan)

Author keywords

In silico screening; Peroxisome Proliferator activated receptor ; Pharmacophore modeling; Quantitative structure activity relationship; Type 2 diabetes mellitus

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; DIABETES MELLITUS; GENETIC ALGORITHM; HYPERGLYCEMIA; IN VITRO STUDY; PHARMACOPHORE; PHYSICOCHEMICAL MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEIVER OPERATING CHARACTERISTIC; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HEP G2 CELLS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PPAR GAMMA; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; ROC CURVE; STEREOISOMERISM;

EID: 79955598528     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.03.040     Document Type: Article

References (89)

1. L.M. Hall, N. Sattar, J.M. Gill, Risk of metabolic and vascular disease in South Asians: potential mechanisms for increased insulin resistance, Future Lipidology 3 (2008) 411-424.
2. B.R. Johns, G.M. Reaven, PPAR-γ agonists, insulin resistance and dyslipidemia: not a simple relationship, Clinical Lipidology 5 (2010) 509-525.
3. P. Arck, B. Toth, A. Pestka, U. Jeschke, Nuclear receptors of the peroxisome proliferator-activated receptor (PPAR) family in gestational diabetes: from animal models to clinical trials, Biology of Reproduction 83 (2010) 168-176.
4. A. Hiukka, M. Maranghi, N. Matikainen, M.R. Taskinen, PPAR alpha: an emerging therapeutic target in diabetic microvascular damage, Nature Reviews Endocrinology 6 (2010) 454-463.
5. A. Farce, N. Renault, P. Chavatte, Structural insight into PPAR γ ligands binding, Current Medicinal Chemistry 16 (2009) 1768-1789.
6. R. Siersbaek, R. Nielsen, S. Mandrup, PPAR γ in adipocyte differentiation and metabolism e novel insights from genome-wide studies, FEBS Letters 584 (2010) 3242-3249.
7. J.S. Bae, T.H. Kim, M.Y. Kim, J.M. Park, Y.H. Ahn, Transcriptional Regulation of glucose sensors in pancreatic beta-cells and liver: an update, Sensors 10 (2010) 5031-5053.
8. J. Bassaganya-Riera, R. Song, P.C. Roberts, R. Hontecillas, PPAR-γ activation as an anti-inflammatory therapy for respiratory virus infections, Viral Immunology 23 (2010) 343-352.
9. S.Z. Duan, M.G. Usher, R.M. Mortensen, PPARs: the vasculature, inflammation and hypertension, Current Opinion in Nephrology and Hypertension 18 (2009) 128-133.
10. B.D. Abbott, Review of the expression of peroxisome proliferator- activated receptors alpha (PPARα), beta (PPARβ), and gamma (PPARγ) in rodent and human development, Reproductive Toxicology 27 (2009) 246-257.
11. E.R. Pearson, Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes, Frontiers in Bioscience 14 (2009) 4348-4362.
12. B.R. Henke, Peroxisome proliferator-activated receptor gamma (PPAR γ) ligands and their therapeutic utility, in: Progress in Medicinal Chemistry. Elsevier, 2004, pp. 1-53.
13. J. Choi, Y. Ko, H.S. Lee, Y.S. Park, Y. Yang, S. Yoon, Identification of (β-carboxyethyl)- rhodanine derivatives exhibiting peroxisome proliferator-activated receptor γ activity, European Journal of Medicinal Chemistry 45 (2010) 193-202.
14. J.H. Ahn, M.S. Shin, S.H. Jung, J.A. Kim, H.M. Kim, S.H. Kim, S.K. Kang, K.R. Kim, S.D. Rhee, S.D. Park, J.M. Lee, J.H. Lee, H.G. Cheon, S.S. Kim, Synthesis and structureeactivity relationship of novel indene N-oxide derivatives as potent peroxisome proliferator activated receptor(PPARγ) agonists, Bioorganic & Medicinal Chemistry Letters 17 (2007) 5239-5244. (Pubitemid 47259645)
15. Y. Lamotte, P. Martres, N. Faucher, A. Laroze, D. Grillot, N. Ancellin, Y. Saintillan, V. Beneton, R.T. Gampe Jr., Synthesis and biological activities of novel indole derivatives as potent and selective PPAR γ modulators, Bioorganic & Medicinal Chemistry Letters 20 (2010) 1399-1404.
16. S.D. Debenham, A. Chan, F.W. Lau, W. Liu, H.B. Wood, K. Lemme, L. Colwell, B. Habulihaz, T.E. Akiyama, M. Einstein, T.W. Doebber, N. Sharma, C.F. Wang, M. Wu, J.P. Berger, P.T. Meinke, Highly functionalized 7-azaindoles as selective PPARγ modulators, Bioorganic & Medicinal Chemistry Letters 18 (2008) 4798-4801.
17. X.-Y. Ye, S. Chen, H. Zhang, K.T. Locke, K. O'Malley, L. Zhang, R. Srivastava, B. Miao, D. Meyers, H. Monshizadegan, D. Search, D. Grimm, R. Zhang, J. Lippy, C. Twamley, J.K. Muckelbauer, C. Chang, Y. An, V. Hosagrahara, L. Zhang, T.J. Yang, R. Mukherjee, P.T.W. Cheng, J.A. Tino, Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPAR α selective activators- PPAR α and PPAR γ selectivity modulation, Bioorganic & Medicinal Chemistry Letters 20 (2010) 2933-2937.
18. R.C. Desai, W. Han, E.J. Metzger, J.P. Bergman, D.F. Gratale, K.L. MacNaul, J.P. Berger, T.W. Doebber, K. Leung, D.E. Moller, J.V. Heck, S.P. Sahoo, 5-Aryl thiazolidine-2,4-diones: discovery of PPAR dual α/γ agonists as antidiabetic agents, Bioorganic & Medicinal Chemistry Letters 13 (2003) 2795-2798.
19. R.C. Desai, D.F. Gratale, W. Han, H. Koyama, E. Metzger, V.K. Lombardo, K.L. MacNaul, T.W. Doebber, J.P. Berger, K. Leung, R. Franklin, D.E. Moller, J.V. Heck, S.P. Sahoo, Aryloxazolidinediones: identification of potent orally active PPAR dual α/γ agonists, Bioorganic & Medicinal Chemistry Letters 13 (2003) 3541-3544. (Pubitemid 37141425)
20. C. Santini, G.D. Berger, W. Han, R. Mosley, K. MacNaul, J. Berger, T. Doebber, M. Wu, D.E. Moller, R.L. Tolman, S.P. Sahoo, Phenylacetic acid derivatives as hPPAR agonists, Bioorganic & Medicinal Chemistry Letters 13 (2003) 1277-1280. (Pubitemid 36351333)
21. T. Kaya, S.C. Mohr, D.J. Waxman, S. Vajda, Computational screening of phthalate monoesters for binding to PPARγ, Chemical Research in Toxicology 19 (2006) 999-1009. (Pubitemid 44384830)
22. M. Scarsi, M. Podvinec, A. Roth, Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor γ activity: a combined virtual screening and biological assay approach, Molecular Pharmacology 71 (2007) 398-406. (Pubitemid 46147906)
23. J. Choi, Y. Ko, H.S. Lee, Y.S. Park, Y. Yang, S. Yoon, Structure based drug design studies on heteroaryl propanoic acid derivatives as PPARγ agonists, European Journal of Medicinal Chemistry 45 (2010) 193-202.
24. M. Hieke, J. Ness, R. Steri, M. Dittrich, C. Greiner, O. Werz, K. Baumann, M. Schubert-Zsilavecz, S. Weggen, H. Zettl, Design, synthesis, and biological evaluation of a novel class of γ-secretase modulators with PPARγ activity, Journal of Medicinal Chemistry 53 (2010) 4691-4700.
25. M. Goebel, M. Clemenz, B. Staels, T. Unger, U. Kintscher, R. Gust, Characterization of new PPARγ agonists: analysis of telmisartan's structural components, ChemMedChem 4 (2009) 445-456.
26. X. Dong, Z. Zhang, R. Wen, J. Shen, X. Shen, H. Jiang, Structure-based de novo design, synthesis, and biological evaluation of the indole-based PPAR γ ligands (I), Bioorganic & Medicinal Chemistry Letters 16 (2006) 5913-5916.
27. B. Kuhn, H. Hilpert, J. Benz, A. Binggeli, U. Grether, R. Humm, H.P. Märki, M. Meyer, P. Mohr, Structure-based design of indole propionic acids as novel PPARα/γ co-agonists, Bioorganic & Medicinal Chemistry Letters 16 (2006) 4016-4020. (Pubitemid 43903212)
28. Y. Iwata, S. Miyamoto, M. Takamura, H. Yanagisawa, A. Kasuya, Interaction between peroxisome proliferator-activated receptor γ and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione, Journal of Molecular Graphics & Modelling 19 (2001) 536-542.
29. C. Liao, B. Liu, L. Shi, J. Zhou, X.-P. Lu, Construction of a virtual combinatorial library using SMILES strings to discover potential structure-diverse PPAR modulators, European Journal of Medicinal Chemistry 40 (2005) 632-640. (Pubitemid 40797559)
30. N. Mahindroo, C.-F. Huang, Y.-H. Peng, C.-C. Wang, C.-C. Liao, T.-W. Lien, S.K. Chittimalla, W.-J. Huang, C.-H. Chai, E. Prakash, C.-P. Chen, T.-A. Hsu, C.- H. Peng, I.L. Lu, L.-H. Lee, Y.-W. Chang, W.-C. Chen, Y.-C. Chou, C.-T. Chen, C.M.V. Goparaju, Y.-S. Chen, S.-J. Lan, M.-C. Yu, X. Chen, Y.-S. Chao, S.-Y. Wu, H.-P. Hsieh, Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities, Journal of Medicinal Chemistry 48 (2005) 8194-8208.
31. Y. Tanrikulu, O. Rau, O. Schwarz, E. Proschak, K. Siems, L. Müller-Kuhrt, M. Schubert-Zsilavecz, G. Schneider, Structure-based pharmacophore screening for natural-product-derived PPARγ agonists, ChemBioChem 10 (2009) 75-78.
32. I.L. Lu, C.-F. Huang, Y.-H. Peng, Y.-T. Lin, H.-P. Hsieh, C.-T. Chen, T.-W. Lien, H.- J. Lee, N. Mahindroo, E. Prakash, A. Yueh, H.-Y. Chen, C.M.V. Goparaju, X. Chen, C.-C. Liao, Y.-S. Chao, J.T.A. Hsu, S.-Y. Wu, Structure-based drug design of a novel family of PPARγ partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities, Journal of Medicinal Chemistry 49 (2006) 2703-2712.
33. X.Y. Xu, F. Cheng, J.H. Shen, X.M. Luo, L.L. Chen, L.D. Yue, Y. Du, F. Ye, S.H. Jiang, D.Y. Zhu, H.L. Jiang, K.X. Chen, Agonist-PPAR γ interactions: molecular modeling study with docking approach, International Journal of Quantum Chemistry 93 (2003) 405-410.
34. S. Sundriyal, P.V. Bharatam, Important pharmacophoric features of pan PPAR agonists: common chemical feature analysis and virtual screening, European Journal of Medicinal Chemistry 44 (2009) 3488-3495.
35. L. Rathi, S.K. Kashaw, A. Dixit, G. Pandey, A.K. Saxena, Pharmacophore identification and 3D-QSAR studies in N-(2-benzoyl phenyl)-L-tyrosines as PPAR γ agonists, Bioorganic & Medicinal Chemistry 12 (2004) 63-69. (Pubitemid 38096218)
36. C.Z. Liao, A.H. Xie, J.J. Zhou, L.M. Shi, Z.B. Li, X.P. Lu, 3D QSAR studies on peroxisome proliferator-activated receptor gamma agonists using CoMFA and CoMSIA, Journal of Molecular Modeling 10 (2004) 165-177.
37. N.K. Salam, T.H.-W. Huang, B.P. Kota, M.S. Kim, Y. Li, D.E. Hibbs, Novel PPAR-γ agonists identified from a natural product library: a virtual screening, induced fit docking and biological assay study, Chemical Biology and Drug Design 71 (2008) 57-70.
38. A. Furukawa, T. Arita, S. Satoh, K. Wakabayashi, S. Hayashi, Y. Matsui, K. Araki, M. Kuroha, J. Ohsumi, Discovery of a novel selective PPAR γ modulator from (-)-cercosporamide derivatives, Bioorganic & Medicinal Chemistry Letters 20 (2010) 2095-2098.
39. Y. Li, Z. Wang, N. Furukawa, P. Escaron, J. Weiszmann, G. Lee, M. Lindstrom, J. Liu, X. Liu, H. Xu, O. Plotnikova, V. Prasad, N. Walker, R.M. Learned, J.-L. Chen, T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor γ binding properties, Journal of Biological Chemistry 283 (2008) 9168-9176.
40. G. Fracchiolla, A. Laghezza, L. Piemontese, P. Tortorella, F. Mazza, R. Montanari, G. Pochetti, A. Lavecchia, E. Novellino, S. Pierno, D. Conte Camerino, F. Loiodice, New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator- activated receptors α/γ dual agonists with improved potency and reduced adverse effects on skeletal muscle function, Journal of Medicinal Chemistry 52 (2009) 6382-6393.
41. A. Motani, Z. Wang, J. Weiszmann, L.R. McGee, G. Lee, Q. Liu, J. Staunton, Z. Fang, H. Fuentes, M. Lindstrom, J. Liu, D.H.T. Biermann, J. Jaen, N.P.C. Walker, R.M. Learned, J.-L. Chen, Y. Li, INT131: a selective modulator of PPAR γ, Journal of Molecular Biology 386 (2009) 1301-1311.
42. T. Waku, T. Shiraki, T. Oyama, Y. Fujimoto, K. Maebara, N. Kamiya, H. Jingami, K. Morikawa, Structural insight into PPAR γ activation through covalent modification with endogenous fatty acids, Journal of Molecular Biology 385 (2009) 188-199.
43. D.R. Artis, J.J. Lin, C. Zhang, W. Wang, U. Mehra, M. Perreault, D. Erbe, H.I. Krupka, B.P. England, J. Arnold, A.N. Plotnikov, A. Marimuthu, H. Nguyen, S. Will, M. Signaevsky, J. Kral, J. Cantwell, C. Settachatgull, D.S. Yan, D. Fong, A. Oh, S. Shi, P. Womack, B. Powell, G. Habets, B.L. West, K.Y.J. Zhang, M.V. Milburn, G.P. Vlasuk, K.P. Hirth, K. Nolop, G. Bollag, P.N. Ibrahim, J.F. Tobin, Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent, Proceedings of the National Academy of Sciences 106 (2009) 262-267.
44. R. Montanari, F. Saccoccia, E. Scotti, M. Crestani, C. Godio, F. Gilardi, F. Loiodice, G. Fracchiolla, A. Laghezza, P. Tortorella, A. Lavecchia, E. Novellino, F. Mazza, M. Aschi, G. Pochetti, Crystal structure of the peroxisome proliferator-activated receptor γ (PPARγ) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design, Journal of Medicinal Chemistry 51 (2008) 7768-7776.
45. V. Chandra, P. Huang, Y. Hamuro, S. Raghuram, Y. Wang, T.P. Burris, F. Rastinejad, Structure of the intact PPAR-γ-RXR- nuclear receptor complex on DNA, Nature (2008) 350-356.
46. M. Einstein, T.E. Akiyama, G.A. Castriota, C.F. Wang, B. McKeever, R.T. Mosley, J.W. Becker, D.E. Moller, P.T. Meinke, H.B. Wood, J.P. Berger, The differential interactions of peroxisome proliferator-activated receptor γ ligands with Tyr473 is a physical basis for their unique biological activities, Molecular Pharmacology 73 (2008) 62-74.
47. Y. Li, M. Choi, K. Suino, A. Kovach, J. Daugherty, S.A. Kliewer, H.E.Xu, Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner, Proceedings of the National Academy of Sciences of the United States of America 102 (2005) 9505-9510.
48. N.R.A. Beeley, C. Sage, GPCRs: an update on structural approaches to drug discovery, Targets 2 (2003) 19-25.
49. G. Klebe, Virtual ligand screening: strategies, perspectives and limitations, Drug Discovery Today 11 (2006) 580-594.
50. H. Steuber, M. Zentgraf, C. Gerlach, C.A. Sotriffer, A. Heine, G. Klebe, Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions, Journal of Molecular Biology 363 (2006) 174-187.
51. M.T. Stubbs, S. Reyda, F. Dullweber, M. Möller, G. Klebe, D. Dorsch, W.W.K.R. Mederski, H. Wurziger, pH-dependent binding modes observed in trypsin crystals: lessons for structure-based drug design, ChemBioChem 3 (2002) 246-249.
52. M.A. DePristo, P.I.W. de Bakker, T.L. Blundell, Heterogeneity and inaccuracy in protein structures solved by X-ray crystallography, Structure 12 (2004) 831-838.
53. B.C. Kallenberger, J.D. Love, V.K.K. Chatterjee, J.W.R. Schwabe, A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease, Nature Structural Biology 10 (2003) 136-140.
54. M.O. Taha, Y. Bustanji, M.A.S. Al-Ghussein, M. Mohammad, H. Zalloum, I.M. Al- Masri, N. Atallah, Pharmacophore modeling, quantitative structureeactivity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3β inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin, Journal of Medicinal Chemistry 51 (2008) 2062-2077.
55. M.O. Taha, L.A. Dahabiyeh, Y. Bustanji, H. Zalloum, S. Saleh, Combining ligand-based pharmacophore modeling, quantitative structureeactivity relationship analysis and in silico screening for the discovery of newpotent hormone sensitive lipase inhibitors, Journal of Medicinal Chemistry 51 (2008) 6478-6494.
56. M.O. Taha, N. Atallah, A.G. Al-Bakri, C. Paradis-Bleau, H. Zalloum, K.S. Younis, R.C. Levesque, Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening, Bioorganic & Medicinal Chemistry 16 (2008) 1218-1235.
57. M.O. Taha, Y. Bustanji, A.G. Al-Bakri, A.-M. Yousef, W.A. Zalloum, I.M. Al-Masri, N. Atallah, Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening, Journal of Molecular Graphics and Modelling 25 (2007) 870-884.
58. A.M. Abu Hammad, M.O. Taha, Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors, Journal of Chemical Information and Modeling 49 (2009) 978-996.
59. M.O. Taha, M. Tarairah, H. Zalloum, G. Abu-Sheikha, Pharmacophore and QSAR modeling of estrogen receptor beta ligands and subsequent validation and in silico search for new hits, Journal of Molecular Graphics & Modelling 28 (2010) 383-400.
60. R. Abu Khalaf, G. Abu Sheikha, Y. Bustanji, M.O. Taha, Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration, European Journal of Medicinal Chemistry 45 (2010) 1598-1617.
61. A. Al-Nadaf, G. Abu Sheikha, M.O. Taha, Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads, Bioorganic & Medicinal Chemistry 18 (2010) 3088-3115.
62. M.A. Al-Sha'er, M.O. Taha, Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay, European Journal of Medicinal Chemistry 45 (2010) 4316-4330.
63. M.A. Al-Sha'er, M.O. Taha, Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90a inhibitors, Journal of Chemical Information and Modeling 50 (2010) 1706-1723.
64. Discovery Studio Version 2.5 (DS 2.5) User Manual. Accelrys Inc, San Diego, CA, 2009.
65. M.O. Taha, A.G. Al-Bakri, W.A. Zalloum, Discovery of potent inhibitors of pseudomonal quorum sensing via pharmacophore modeling and in silico screening, Bioorganic & Medicinal Chemistry Letters 16 (2006) 5902-5906.
66. K. Liu, R.M. Black, J.J. Acton Iii, R. Mosley, S. Debenham, R. Abola, M. Yang, R. Tschirret-Guth, L. Colwell, C. Liu, M. Wu, C.F. Wang, K.L. MacNaul, M.E. McCann, D.E. Moller, J.P. Berger, P.T. Meinke, A.B. Jones, H.B. Wood, Selective PPAR γ modulators with improved pharmacological profiles, Bioorganic & Medicinal Chemistry Letters 15 (2005) 2437-2440.
67. R.C. Desai, E. Metzger, C. Santini, P.T. Meinke, J.V. Heck, J.P. Berger, K.L. MacNaul, T.-Q. Cai, S.D. Wright, A. Agrawal, D.E. Moller, S.P. Sahoo, Design and synthesis of potent and subtype-selective PPARa agonists, Bioorganic & Medicinal Chemistry Letters 16 (2006) 1673-1678.
68. H. Li, J. Sutter, R. Hoffman, HypoGen: an automated system for generating 3D predictive pharmacophore models. in: O. Guner (Ed.), Pharmacophore Perception, Development and Use in Drug Design. International University Line, 2000, pp. 173-189.
69. H. Li, J. Sutter, R. Hoffman, O. Guner, Effect of variable weights and tolerances on predictive model generation. in: O. Guner (Ed.), Pharmacophore Perception, Development and Use in Drug Design. International University Line, 2000, pp. 501-511.
70. K. Poptodorov, T. Luu, T. Langer, R. Hoffmann, Pharmacophores and Pharmacophores Searches, second ed. Wiley-VCH, Weinheim, Germany, 2006.
71. Y. Kurogi, O.F. Guner, Pharmacophore modeling and three-dimensional database searching for drug design using catalyst, Current Medicinal Chemistry 8 (2001) 1035-1055.
72. I. Bersuker, S. Bahçeci, J. Boggs, The electron-conformational method of identification of pharmacophore and anti pharmacophore shielding. in: O. Guner (Ed.), Pharmacophore Perception, Development and Use in Drug Design. International University Line, 2000, pp. 457-473.
73. R. Fischer, The Principle of Experimentation Illustrated by a Psycho-Physical ExpeHafner Publishing Co, eighth ed. Hafner Publishing, New York, 1966.
74. I. Al-masri, M. Mohammad, M. Taha, Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening, ChemMedChem 3 (2008) 1763-1779.
75. F.L. Ramsey, D.W. Schafer, The Statistical Sleuth: a Course in Methods of Data Analysis, first ed. Wadsworth Publishing Company, Belmont, CA, 1997.
76. M.L. Verdonk, V. Berdini, M.J. Hartshorn, W.T.M. Mooij, C.W. Murray, R.D. Taylor, P. Watson, Virtual screening using proteineligand docking: avoiding artificial enrichment, Journal of Chemical Information and Computer Sciences 44 (2004) 793-806.
77. J. Kirchmair, P. Markt, S. Distinto, G. Wolber, T. Langer, Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection e what can we learn from earlier mistakes? Journal of Computer-Aided Molecular Design 22 (2008) 213-228.
78. J.J. Irwin, B.K. Shoichet, ZINC e a free database of commercially available compounds for virtual screening, Journal of Chemical Information and Modeling 45 (2004) 177-182.
79. N. Triballeau, F. Acher, I. Brabet, J.-P. Pin, H.-O. Bertrand, Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4, Journal of Medicinal Chemistry 48 (2005) 2534-2547.
80. C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Advanced Drug Delivery Reviews 46 (2001) 3-26.
81. D.F. Veber, S.R. Johnson, H.-Y. Cheng, B.R. Smith, K.W. Ward, K.D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates, Journal of Medicinal Chemistry 45 (2002) 2615-2623.
82. D. Debendranath, M. Satya, N. Partha, G. Maya, C. Jin, G. Coleman, D.S. Somesh, M.R. Gerald, N. Bishwajit, A novel peroxisome proliferator-activated gamma (PPARg) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential, Metabolism: Clinical and Experimental 52 (2003) 1012-1018.
83. P. Neogi, F.J. Lakner, S. Medicherla, J. Cheng, D. Dey, M. Gowri, B. Nag, S.D. Sharma, L.B. Pickford, C. Gross, Synthesis and structure-activity relationship studies of cinnamic acid-based novel thiazolidinedione antihyperglycemic agents, Bioorganic & Medicinal Chemistry 11 (2003) 4059-4067.
84. S.-K. Lin, Pharmacophore perception, development and use in drug design. in: Osman F. Güner (Ed.), Molecules, 5, 2000, pp. 987-989.
85. G. Osman, C. Omoshile, K. Yasuhisa, Pharmacophore modeling and three dimensional database searching for drug design using catalyst: recent advances, Current Medicinal Chemistry 11 (2004) 2991-3005.
86. E.M. Krovat, T. Langer, Impact of scoring functions on enrichment in dockingbased virtual screening: an application study on renin inhibitors, Journal of Chemical Information and Computer Sciences 44 (2004) 1123-1129.
87. M. Jacobsson, P. Lidén, E. Stjernschantz, H. Boström, U. Norinder, Improving structure-based virtual screening by multivariate analysis of scoring data, Journal of Medicinal Chemistry 46 (2003) 5781-5789.
88. H. Gao, C. Williams, P. Labute, J. Bajorath, Binary quantitative structure-activity relationship (QSAR) analysis of estrogen receptor ligands, Journal of Chemical Information and Computer Sciences 39 (1998) 164-168.
89. S. Park, I.S. Ahn, J.H. Kim, M.R. Lee, J.S. Kim, H.J. Kim, Glyceollins, one of the phytoalexins derived from soybeans under fungal stress, enhance insulin sensitivity and exert insulinotropic actions, Journal of Agricultural and Food Chemistry 58 (2010) 1551-1557.